Other languages Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
11.89 ^CNY	-0.17%		-2.54%	-12.44%

05-21	Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	MT
04-26	Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	05-21
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	04-25
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	12-06
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	11-06
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	23-09-21
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	23-09-21
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	23-07-12
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	23-07-11
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	23-05-17
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	23-03-27
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial	23-02-28
Hybio Pharma's Controlling Shareholder and Party Acting in Concert Plan to Unload Stake	23-02-13
Hybio Pharma Registers New Pen Injector Medical Device	23-01-22
Hybio Pharmaceutical Sees Loss of Up to 380 Million Yuan for 2022	23-01-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hybio Pharmaceutical Co., Ltd.

Equities

300199

CNE1000011T7

Other languages

Filters